Pharmaceutical companies "abandon" to adjust product layout, and some generic pharmaceutical businesses are abandoned

[industry trends of pharmaceutical network] generic medicine refers to a kind of generic product which is the same or similar to the commercial drugs in terms of dosage, efficacy, function and indications China is a big country of generic drugs, which accounts for more than 90% of the whole drug market In order to encourage the development of high-quality generic drugs and reduce the cost of drug use for patients, at the beginning of October this year, the national health and Health Commission issued the catalogue of approved and encouraged generic drugs, which clearly listed the first 33 catalogue of encouraged generic drugs, and proposed that all relevant departments should provide support in clinical trials, key generic technology research, priority review and approval in accordance with relevant regulations, which also gave research and development of generic drugs enterprises The direction is pointed out to avoid blind production of pharmaceutical enterprises It is understood that 21 of the 33 categories of generic drugs encouraged are products that have not been listed on the market at home and abroad, and 9 of them are generic drugs in China Among them, formoterol fumarate inhalation solution, fluvistrane injection, fosapride dimethylmeglumine injection sterile powder and other products are under development in Zhengda Tianqing, some of which have been applied for production In addition, since this year, under the background of 4 + 7 volume procurement, medical insurance and fee control, the pharmaceutical pattern has changed, and the profit space of generic pharmaceutical enterprises has been greatly compressed, so they are facing greater survival challenges In this context, some enterprises began to adjust the company's product layout and abandon some generic pharmaceutical businesses to adapt to the market development It is reported that local leading enterprises Hengrui pharmaceutical, Zhengda Tianqing, Shiyao group, Kelun pharmaceutical, Xiansheng pharmaceutical, etc have abandoned low-end generic drugs and started to embark on the road of high-tech barriers to the combination of generic drugs and innovative drug research and development For example, based on the measurement of input and output, Hengrui pharmaceutical stopped general generic pharmaceutical projects as early as 2018 Sun piaoyan, chairman of Hengrui pharmaceutical, said at an industry meeting that to change the current situation of enterprises and have more competitive advantages, we must take the road of innovation Recently, Hengrui announced to suspend general generic drug projects and only make innovative drugs and core value generic drugs It can be seen that in the future, enterprises with the first mover advantage in the innovative pharmaceutical industry will have more say The head of Zhengda Tianqing once said that with the nationwide expansion of volume procurement, generic drugs will enter the era of low profit in the future, and generic drugs and innovative drugs with high technical barriers will become the research and development direction of pharmaceutical enterprises 70% of the products newly approved by the company in 2019 are innovative drugs Shiyao group, the head enterprise of generic drugs, has begun to make efforts in new target macromolecular biological drugs, small molecule new drugs, protochemicals and other three categories of new drugs The research and development direction of generic drugs has also turned to generic drugs with high-tech content Kelun pharmaceutical has a wide range of innovative drugs and rich reserves of generic projects It is expected to obtain 11 generic production approvals in 2019-2020, and 8 varieties are expected to pass the consistency evaluation At the same time, Coelen has launched more than 490 drug researches for domestic and foreign markets, including 392 generic drugs (including consistency evaluation varieties), 20 new drug delivery system drugs (NDDs) and 80 innovative drug researches, and generic drugs have gradually blossomed As early as the beginning of 2018, Xiansheng pharmaceutical announced the establishment of Shanghai innovation center, and separated the research and development of generic drugs and innovative drugs into two independent management, completely abandoning low-end generic drugs It can be seen that the horn of the transformation of generic pharmaceutical enterprises has been sounded Analysts judge that under the pressure of quality upgrading, at least 3000 of China's more than 4000 pharmaceutical manufacturers will be eliminated With the promotion of the 4 + 7 volume procurement expansion policy, this reshuffle has accelerated.